HCV New Drugs: Treatment of HCV‐Associated Extrahepatic Manifestations in 2018

Clinical Liver Disease
© The American Association for the Study of Liver Diseases
Clinical Liver Disease (CLD) is an online learning resource of AASLD offering research articles with audio, video, webinars, and other interactive content designed for any physician or healthcare provider caring for a patient with liver disease.

Here is the latest June content:

Reviews

Guest Edited by Elizabeth May, MD

Treatment of the extrahepatic manifestations of chronic hepatitis C infection

Karn Wijarnpreecha M.D.
Wisit Cheungpasitporn M.D.
Surakit Pungpapong M.D.
Kiran R. Nakkala M.D., M.P.H.

When we look at the landscape in 2018, we find that the guidelines of the American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA) and European Association for the Study of the Liver (EASL) are in agreement that all patients with HCV infection should be treated with effective antiviral therapy.3, 4 Table 2 categorizes HCV‐associated EHMs according to severity.5 Treatment of patients with mild‐to‐moderate HCV‐associated EHMs is important because the first‐line treatment of HCV‐associated EHMs of mild‐to‐moderate severity is always initiation of DAA therapy. Patients with severe or life‐threatening EHMs of HCV should also receive the most appropriate DAAs....
Pages: 115-118
First Published:05 June 2018
Watch a video presentation of this article
Watch the interview with the author
Answer questions and earn CME
Abstract
Full text
PDF
References
Request permissions

Risk factors, scoring systems, and interventions for alcohol relapse after liver transplantation for alcoholic liver disease

Jane Lim M.D.

Vinay Sundaram M.D., M.Sc.